Endometriosis: current therapies and new pharmacological developments
Paolo Vercellini1, Edgardo Somigliana, Paola Viganò
1Clinica Ostetrica e Ginecologica I, University of Milan, Milan, Italy. paolo.vercellini@unimi.it
Drugs
|May 2, 2009
Summary
Endometriosis management involves hormonal therapies to suppress symptoms, but current treatments are not curative. Combined oral contraceptives and progestins are recommended first-line options for endometriosis pain relief.
Area of Science:
- Gynecology
- Reproductive Medicine
- Pharmacology
Background:
- Endometriosis is a chronic inflammatory condition characterized by ectopic endometrial tissue.
- Hormonal fluctuations and inflammation significantly contribute to endometriosis-associated pain.
Purpose of the Study:
- To review current pharmacological management strategies for endometriosis.
- To evaluate the efficacy and safety of various treatment options.
Main Methods:
- Review of existing literature on endometriosis pharmacotherapy.
- Analysis of clinical trial data for combined oral contraceptives, progestins, GnRH analogues, danazol, and gestrinone.
Main Results:
- Combined oral contraceptives and progestins demonstrate favorable safety, tolerability, and cost-effectiveness as first-line treatments.
- Similar efficacy is observed across various investigated therapies for endometriosis.
- Gonadotrophin-releasing hormone analogues, danazol, or gestrinone are alternatives when first-line options fail or are contraindicated.
Conclusions:
- Pharmacological management of endometriosis aims to suppress symptoms, not cure the condition, often requiring long-term use.
- First-line therapy should prioritize combined oral contraceptives and progestins due to their favorable profiles.
- Medical treatment does not improve reproductive outcomes and is not indicated for women seeking conception.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...